Frequently

Imbue currently provides telehealth weight loss services in the following states: Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Georgia, Hawaii, Iowa, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Maine, Michigan, Minnesota, Missouri, Montana, North Dakota, Nebraska, New Hampshire, New Jersey, Nevada, New York, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Utah, Vermont, Washington, Wisconsin, West Virginia, and Wyoming.

We are actively expanding and plan to be available in all 50 states by Q2 2025, ensuring access to our expert-led, innovative weight loss solutions nationwide.

Our weight loss program includes regular check-ins with your healthcare provider to monitor progress and adjust your treatment plan as needed. You will have access to virtual consultations and a secure messaging platform, allowing you to receive ongoing support, ask questions, and provide updates on your progress. This ensures you stay on track and get the personalized feedback necessary for success.

Our program may not be appropriate for everyone. Candidates must be at least 18 years old, reside in a state where we offer our tele-health services, and meet specific health criteria, which include a thorough evaluation of co-morbidities, past medical history, and current health status. Our providers will assess your individual circumstances to determine whether Imbue is the right fit for your weight loss journey.

Licensed healthcare providers at Imbue prescribe medications like Zepbound® and Wegovy® after reviewing your medical history and assessing your individual health needs. All prescriptions are tailored to ensure safety and effectiveness based on your unique profile.

In most cases, blood tests are not required before getting a prescription for Zepbound® and Wegovy®. However, your healthcare provider may recommend certain tests to assess your overall health, check for underlying conditions, or monitor factors like blood sugar, kidney function, and cholesterol levels. These tests help ensure that Zepbound® and Wegovy® are a safe and effective option for you. If you have a history of metabolic conditions, diabetes, or other health concerns, your provider may suggest additional screenings before starting treatment.

Imbue’s program fee is collected online at the time of enrollment, with a $49.99 monthly fee that covers provider consultations, prescription review, and ongoing medical support. Medication costs are separate and will be paid directly to LillyDirect™ or NovoCare® upon prescription approval.

The monthly cost of Zepbound® vials through LillyDirect™ is $349 for the 2.5 mg dose, and $499 for the 5 mg, 7.5 mg and 10 mg doses.

The monthly cost of Wegovy® pens through NovoCare® is $499 for the 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg doses.

Once prescribed, your medication is shipped directly to your home through LillyDirect™ or NovoCare®, ensuring you receive genuine Zepbound® or Wegovy® straight from the manufacturer. Both LillyDirect™ and NovoCare® handle fulfillment and delivery, making it easy and convenient to get your medication delivered to your doorstep.

You can reach out to our support team or your healthcare provider through our secure online portal at any time. We’re here to help answer your questions, address any concerns, and provide guidance throughout your weight loss journey.

No, insurance is not required. Imbue’s program is a self-pay service, with medication provided through LillyDirect™ for Zepbound® and NovoCare™ for Wegovy®. This ensures you can access the program and receive your medication without needing insurance authorization or coverage.

Individual results vary, but most patients begin noticing changes in the first few months. The program is designed to help you achieve sustainable, long-term weight loss, so consistency with your medication, diet, and exercise plan will maximize your results.

Zepbound® (tirzepatide) is an injectable prescription medication used for chronic weight management. It works by activating two hormones, GLP-1 and GIP, which help regulate appetite and blood sugar. This results in reduced hunger and better blood sugar control, making it easier to lose weight when combined with a reduced-calorie diet and increased physical activity​.

Zepbound® is intended for adults who have a BMI of 30 or higher (obesity) or a BMI of 25 or higher with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol. It is not recommended for people with a history of pancreatitis or certain thyroid conditions.

Zepbound® is given as a once-weekly injection under the skin (subcutaneously). It can be injected in the abdomen, thigh, or upper arm. Your healthcare provider will instruct you on the proper injection technique.

The starting dose of Zepbound® is 2.5 mg once a week for the first four weeks. After this period, the dose is increased to 5 mg per week. Depending on your response to the medication, your doctor may gradually increase the dose up to a maximum of 15 mg per week.

If you miss a dose, take it as soon as you remember, as long as it’s within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume your regular dosing schedule. Never take two doses at the same time.

The most common side effects include nausea, vomiting, diarrhea, constipation, and injection site reactions. These symptoms usually decrease over time as your body adjusts to the medication. Serious side effects, such as pancreatitis, kidney issues, or gallbladder problems, are rare but possible. If you experience severe abdominal pain, persistent vomiting, or other concerning symptoms, contact your healthcare provider immediately.

Zepbound® is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It’s also not recommended for individuals with severe gastrointestinal conditions like gastroparesis. Additionally, Zepbound® is not safe for use during pregnancy.

Most patients start to see weight loss within the first few months of treatment, but the rate of weight loss varies from person to person. Results are typically more noticeable when Zepbound® is combined with a reduced-calorie diet and regular physical activity.

Wegovy® (semaglutide) is an injectable prescription medication used for chronic weight management. It works by mimicking the GLP-1 hormone, which helps regulate appetite and food intake. This leads to reduced hunger and increased feelings of fullness, making it easier to achieve and maintain weight loss when combined with a healthy diet and exercise.

Wegovy® is approved for adults with a BMI of 30 or higher (obesity) or a BMI of 25 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It is not recommended for people with a history of pancreatitis, certain thyroid conditions, or severe gastrointestinal disorders.

Wegovy® is given as a once-weekly injection under the skin (subcutaneous). It can be injected into the abdomen, thigh, or upper arm. Your healthcare provider will show you how to administer the injection properly.

The recommended starting dose of Wegovy® is 0.25 mg once weekly for the first four weeks. The dose is then increased gradually over several weeks to help minimize side effects, reaching a maintenance dose of either 1.7 mg or 2.4 mg once weekly.

If you miss a dose and your next scheduled dose is more than 48 hours away, take the missed dose as soon as possible. If your next dose is less than 48 hours away, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time.

Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. These symptoms typically improve as your body adjusts to the medication. More serious side effects, though rare, can include pancreatitis, gallbladder problems, kidney issues, and severe allergic reactions. If you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction, contact your healthcare provider immediately.

Wegovy® is not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), severe gastrointestinal disorders, such as gastroparesis or a history of pancreatitis. Additionally, Wegovy® should not be used during pregnancy or while breastfeeding.

Many patients start noticing weight loss within the first few months of treatment. However, results vary based on individual factors, and Wegovy® works best when combined with a reduced-calorie diet and increased physical activity.